alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–23 of 23 studies with an author at Flinders University (AU) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Maintain Your Brain: Protocol of a 3-Year Randomized Controlled Trial of a Personalized Multi-Modal Digital Health Intervention to Prevent Cognitive Decline Among Community Dwelling 55 to 77 Year Olds

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of Alzheimer's disease : JAD 2019-01-01

MYB will be the largest internet-based trial to attempt to prevent cognitive decline and potentially dementia. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Barriers and Consequences of Prior Authorization for Neurologic Medications

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Neurology 2025-12-08

A total of 364 studies were identified using our search strategy on Ovid, 278 records were screened, and 20 studies were included in this review. 5 key findings →

Design: meta-analysis Participants: 364 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

What does the general public understand about prevention and treatment of dementia? A systematic review of population-based surveys

✓ Peer-reviewed alzhub usefulness score 60 out of 100. PloS one 2018-04-19

Knowledge among those living in low- and middle-income countries are largely unknown, presenting challenges for the development of National action plans consistent with World Health Organization directives. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluating the effects of the World Health Organisation's online intervention 'iSupport lite' to reduce burden in multilingual dementia carers: results from the Australian Draw-Care randomised clinical trial

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Age and ageing 2026-02-01

One hundred sixteen participants consented and 93 (46 waitlist control, 47 intervention) were included in the analyses. 3 key findings →

Design: RCT Participants: 93 Evidence: null result

Full summary, score breakdown and related studies → Original source Free full text

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Journal of biological chemistry 2006-07-17

A comprehensive, unbiased inventory of synuclein forms present in Lewy bodies from patients with dementia with Lewy bodies was carried out using two-dimensional immunoblot analysis, novel sandwich enzyme-linked immunosorbent assays with modification-specific synuclein antibodies, and mass spectroscopy. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Annals of neurology 1995-11-01

The pathogenesis of human immunodeficiency virus (HIV)-associated dementia is unclear, and the underlying pathological substrate has been a matter of debate. 4 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prediction of Postoperative Delirium in Geriatric Hip Fracture Patients: A Clinical Prediction Model Using Machine Learning Algorithms

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Geriatric orthopaedic surgery & rehabilitation 2021-12-13

The clinical prediction model can play a beneficial role in decision-making for preventative measures for patients at risk of developing a delirium. 3 key findings →

Participants: 207 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The risk of delirium or dementia‐related hospitalization among individuals living with dementia after long‐term care entry: A population‐based risk prediction model

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer s & Dementia 2025-08-01

Within 365 days, 5.2% (N = 10709) of individuals had a delirium or dementia-related hospitalization. 5 key findings →

Participants: 207,343 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Quality and safety indicators for home care recipients in Australia: development and cross-sectional analyses

✓ Peer-reviewed alzhub usefulness score 48 out of 100. BMJ Open 2022-08-01

A comprehensive outcome monitoring system to monitor the quality and safety of care and variation for HCP recipients was developed. 1 key finding →

Design: cross-sectional Participants: 68 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Annals of neurology 1996-06-01

Human immunodeficiency virus type 1 (HIV-1) infects the brains of a majority of patients with the acquired immunodeficiency syndrome (AIDS), and has been linked to the development of a progressive dementia termed "HIV-associated dementia." 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Identifying dementia risk profiles for targeted interventions: A latent class analysis of at‐risk middle‐aged Australians

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s & Dementia 2025-11-01

Among 403 participants (mean age 56.4 ± 5.7 years, 62.5% female), the median number of dementia risk factors was 5.0; hyperlipidaemia (92.5%), low cognitive activity (72.5%), obesity (57.6%), and hypertension (52.7%) were the most prevalent. 5 key findings →

Design: cross-sectional Participants: 403 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mind your nose: A randomized controlled trial of olfactory‐based memory training for older people with subjective cognitive decline

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-07-01

Consistent with previous research, transfer gains from the OMT condition to an untrained VM task suggest that olfaction may contribute to a‐modal representations of memory. 3 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer's research & therapy 2019-12-17

Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. 4 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

How does Australian primary care face dementia? Identifying current practice and barriers in dementia diagnosis and management in Australian primary care – a qualitative interview study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. BMC Family Practice 2026-03-21

Four themes described current primary care practitioner practices in dementia diagnosis and management (1) Family concern triggers dementia investigation (2) GPs delay conversations about dementia (3) Completing routine cognitive assessments in the 75+ health assessment, and (4) Variability in post-diagnostic care. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed